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Abstract
Background: Measure Yourself Medical Outcome Profile (MYMOP) is a patient generated outcome instrument
applicable in the evaluation of both allopathic and complementary medicine treatment. This study aims to adapt
MYMOP into Chinese, and to assess its validity, responsiveness and minimally important change values in a sample
of patients using Chinese medicine (CM) services.
Methods: A Chinese version of MYMOP (CMYMOP) is developed by forward-backward-forward translation strategy,
expert panel assessment and pilot testing amongst patients. 272 patients aged 18 or above with subjective
symptoms in the past 2 weeks were recruited at a CM clinic, and were invited to complete a set of questionnaire
containing CMYMOP and SF-36. Follow ups were performed at 2
nd and 4
th week after consultation, using the same
set of questionnaire plus a global rating of change question. Criterion validity of CMYMOP was assessed by its
correlation with SF-36 at baseline, and responsiveness was evaluated by calculating the Cohen effect size (ES) of
change at two follow ups. Minimally important difference (MID) values were estimated via anchor based method,
while minimally detectable difference (MDC) figures were calculated by distribution based method.
Results: Criterion validity of CMYMOP was demonstrated by negative correlation between CMYMOP Profile scores
and all SF-36 domain and summary scores at baseline. For responsiveness between baseline and 4
th week follow
up, ES of CMYMOP Symptom 1, Activity and Profile reached the moderate change threshold (ES>0.5), while
Symptom 2 and Wellbeing reached the weak change threshold (ES>0.2). None of the SF-36 scores reached the
moderate change threshold, implying CMYMOP’s stronger responsiveness in CM setting. At 2
nd week follow up,
MID values for Symptom 1, Symptom 2, Wellbeing and Profile items were 0.894, 0.580, 0.263 and 0.516 respectively.
For Activity item, MDC figure of 0.808 was adopted to estimate MID.
Conclusions: The findings support the validity and responsiveness of CMYMOP for capturing patient centred
clinical changes within 2 weeks in a CM clinical setting. Further researches are warranted (1) to estimate Activity
item MID, (2) to assess the test-retest reliability of CMYMOP, and (3) to perform further MID evaluation using
multiple, item specific anchor questions.
Background
Given the fundamental differences between allopathic
medicine and traditional, complementary and alternative
medicine (TCAM), conventional approaches in clinical
research may not be directly applicable to the evaluation
of TCAM [1-3]. One of the major challenges in designing
TCAM clinical study is the need in adopting appropriate
outcome measures that is compatible with the complex-
ity of TCAM interventions [4,5]. Understanding the
effect of TCAM from patients’ own perspective is a plau-
sible starting point for evaluation [6,7]. This mandates
the development of patient centred measurement tools
that are able to balance the requirement of capturing
TCAM specific effects, as well as maintaining optimal
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come Profile (MYMOP) is an exemplar tool in this regard
as it is a brief validated instrument that measure changes
based on patients’ subjective preference and assessment
[8]. During MYMOP administration, patients are invited
to nominate one or two symptoms which are especially
of concern to them, together with one daily activity that
is being limited by these symptoms. The respondent then
rates these items, plus a question on general wellbeing,
on a 7 point scale ranging from “as good as it could be”
to “as bad as it could be”. A profile score can be calcu-
lated by averaging individual item score.
As an evaluative tool, MYMOP has been found to be
applicable in both allopathic and TCAM clinical settings
[9], with a particular strength in being more responsive
than SF-36 [8]. Qualitative evaluation of MYMOP sug-
gested that there is a good concordance between TCAM
patients’ personal account of clinical changes and the
quantified description by MYMOP [10], despite its lim-
itations in overcoming response shifts and in capturing
changes in new or episodic symptoms over time[11,12].
MYMOP has been increasingly adopted in the evalua-
tion of TCAM programs in the past decade [13-17].
In China, a clinical efficacy driven approach for evaluat-
ing Chinese medicine (CM) has been advocated as a
research priority, and this calls for conducting more
rigorously designed CM trials with appropriate out-
comes [3]. Nevertheless, few patient centred clinimetric
tools for TCAM evaluation are currently available to
Chinese researchers as most of them are developed in
English [18]. In this study, we aim to assess the validity,
responsiveness and minimally important change of a
Chinese version of MYMOP, in a CM clinical setting in
China.
Methods
Forward - Backward - Forward Translation of MYMOP
In translating MYMOP from English to Chinese, we fol-
lowed guideline developed by Beaton and colleagues
[19]. First, forward translation were performed by one
investigator with clinical and health service research
method training (VC), and one professional translator
(T1) without healthcare background. Two forward trans-
lations of MYMOP were hence generated (MYMOP -
Forward1 and MYMOP - Forward2). By discussion
between VC, LCH and T1, a single consensus based
Chinese translation was produced (MYMOP - For-
ward3). Second, MYMOP - Forward3 was back trans-
lated into English by two Chinese translator (T2 and
T3) residing in the U.S. Two back translated English
versions (MYMOP - Backward1 and MYMOP - Back-
ward2) were generated. SG and SW, who are academic
clinicians in public health and primary care, discussed
discrepancies in the two backward translations and
produced a single harmonised version of back transla-
tion (MYMOP - Backward3). Third, VC, LCH and
another professional translator (T4) worked collabora-
tively and translated MYMOP - Backward3 into Chinese
(MYMOP - Forward4).
Pilot testing of translated version
The semantic and conceptual equivalence between origi-
nal MYMOP and MYMOP - Forward4 was evaluated by
an expert panel consisting of 15 healthcare professionals
with diverse backgrounds. One to one cognitive debrief-
ing interviews were conducted amongst panel members
and their comments on each item were noted. VC,
LCH and SW analysed these qualitative comments and
performed amendments to the items. Feedback about
the changes were then sought from all expert panel
members, and a new consensus based version was
generated (MYMOP - Forward5). Finally, MYMOP -
Forward5 was piloted in 28 patients who had experience
in using allopathic medicine as well as CM. Each patient
was invited to complete the questionnaire, and was
interviewed about the meaning of each item following a
cognitive debriefing approach. Findings from the patient
pilot were analysed by the authors and a final Chinese
version was produced (CMYMOP). Besides MYMOP,
our translation and pilot testing process also included
the Chinese adaptation of a question on patient per-
ceived global change, which was used in the original
MYMOP validation (How would you rate your condi-
tion now compared to the last time you measure it?:
Much better/A little better/About the same/A little
worse/Much worse) [8]. In this study, this question is
used as an anchor question for estimating minimal
important difference of CMYMOP scorings.
Setting and sampling
We performed a single group longitudinal study from
July to December 2008 with consecutive patients who
attended the Yan Chai Hospital cum The Chinese Uni-
versity of Hong Kong Chinese Medicine Training and
Research Centre (YC CMCTR), operated by Yan Chai
Hospital Board in tripartite collaboration with the Hos-
pital Authority and the Chinese University of Hong
Kong. YCCMCTR provides Chinese herbal medicine,
acupuncture and therapeutic massage services. At enrol-
ment, patients were informed on study purpose, and
were assessed for study eligibility by a CM practitioner
(CMP) before consultation. Inclusion criteria were: (1)
aged 18 or above, (2) able to provide written Informed
consent, (3) able to read and write Chinese without
assistance, (4) self reported to suffer from at least one
specific symptoms for in the last 14 days. Exclusion
criteria were: (1) those reported no specific, subjective,
symptomatic complaint in the past 14 days, and
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number for follow up.
Data collection and follow up
After consultation, eligible patients were invited to com-
plete a questionnaire package containing CMYMOP,
previously validated Hong Kong Chinese version of
SF-36[20], as well as health and demographic questions.
Follow up assessments using CMYMOP, SF-36 and
patient perceived change question were performed at
2
nd and 4
th week post consultation, either via face to
face or telephone interview. In both formats, reminders
on baseline CMYMOP Symptoms 1, Symptom 2 and
Activities entries were given, but previous scorings were
concealed. For time frame of reference, we used “past
7d a y s ” at baseline, and “past two weeks” for follow-ups.
The time frame of reference for follow ups was one
week longer than the original English version. This
change is grounded on our pilot results, which sug-
gested that many patients found it difficult to isolate
their subjective experience in the past 7 days when they
performed follow up after two weeks. A trained CMP
assisted patients in all episodes of data collection, but
patients were strongly encouraged to follow their own
perspective when scoring each CMYMOP and SF-36
items. A small gift was given to each enrolled patient as
an incentive. Ethics approval was obtained from Chinese
University of Hong Kong Clinical Research Ethics
Committee.
Data analysis
Criterion validity of CMYMOP was assessed by the
strength of correlation between CMYMOP and SF-36
scores at baseline. Based on previous study which
showed low to moderate correlation between MYMOP
and SF-36 scorings, the Pearson product-moment corre-
lation coefficients between the two scores were hypothe-
sized to range between 0.20-0.60 [8]. These coefficients
were also expected to have a minus sign, as improve-
ment is denoted by an increase in SF-36 scores, or a
decrease in CMYMOP scores.
The statistical significance of change scores from base-
line to two follow ups, as well as between follow ups
were assessed by paired t-test. Following Norman et al.’s
recommendation [21], responsiveness of CMYMOP was
evaluated by calculating the Cohen’s effect size (ES) of
mean change scores at various intervals (baseline to 2
nd
and 4
th week follow ups, and between 2
nd and 4
th week
follow up). ES was calculated by dividing mean change
scores with standard deviation (SD) of baseline mean
scores. ES values of 0.20, 0.50, and 0.80 or greater was
adopted to represent weak, moderate, and strong
responsiveness [21].
We estimated minimal important difference (MID)
and minimal detectable change (MDC) values of CMY-
MOP using anchor and distribution based approach
respectively [22]. For MID, as we asked patient per-
ceived change questions on two occasions (1. Early
anchor: differences between baseline and 2
nd week
follow up, and 2. Late anchor: differences between 2
nd
week and 4
th week follow up), we were able to estimate
MID using two anchors with different timeframe. For
both anchors, MID values were regarded as the mean
change scores of patients who indicated that they were
“a little better” [23]. The corresponding MDC values
were calculated by halving the SD of mean change
scores [24]. All statistical analyses were performed by
SPSS 15 software.
Results
Response and sample characteristics
At baseline, 539 were enrolled. At 2 weeks, 343 patients
were followed up successfully (227 face to face inter-
views, 116 telephone interviews, response rate from
baseline = 63.6%). 272 patients were followed up at
4 week (156 face to face interviews, 116 telephone inter-
views, response rate from baseline = 50.5%). The demo-
graphic and health characteristics of patients who
completed all follow ups are presented in table 1.
Criterion validity and responsiveness of CMYMOP
For criterion validity, all SF-36 domain and summary
scores exhibited low to moderate correlation with CMY-
MOP profile score at baseline. All Pearson product-
moment correlation coefficient values were negative and
statistically significant, ranging from -0.314 to -0.454
(all p < 0.01, table 2).
For responsiveness between baseline and 4
th week
f o l l o wu p ,E So fC M Y M O PS y m p t o m1 ,A c t i v i t ya n d
Profile reached the moderate change threshold (ES>0.5),
while Symptom 2 and Wellbeing reached the weak
change threshold (ES>0.2). For baseline to 2
nd week fol-
low up, ES of Activity reached moderate change thresh-
old, and the remaining ES attained weak change
threshold except Wellbeing. None of the ES between
2
nd and 4
th week follow up achieved weak or moderate
threshold. Finally, ES of all SF-36 domains at all time
frames failed to reach the moderate change threshold
(Table 3).
Table 4 shows baseline to 2
nd week CMYMOP mean
change scores by varying degrees of patient perceived
change. Distribution of mean change scores demon-
strated the expected increment down the perceived
global change gradient. This pattern resembled findings
in the validation study of original English MYMOP [8].
However, for Activity item, our mean change scores for
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Page 3 of 9Table 1 Participant characteristics
n%
Gender Male 44 16.2
Female 228 83.8
Age <20 12 4.4
20-29 37 13.6
30-39 60 22.1
40-49 61 22.4
50-59 58 21.3
60-69 26 9.6
70-79 16 5.9
>79 2 0.7
Highest Education Attained Never received formal education/attended kindergarten 2 0.7
Completed primary school 42 15.4
Completed junior high school 60 22.1
Completed high school 94 34.6
Completed post-secondary education 29 10.7
Completed undergraduate education 31 11.4
Completed postgraduate education 14 5.1
Marital Status Never married 84 30.9
Married 155 57.0
Widowed 8 2.9
Divorced/Separated 21 7.7
Refused to answer 4 1.5
Employment status Employed full time 104 38.2
Employed part time 29 10.7
Unemployed 136 50.0
Refused to answer 3 1.1
Current attendance to full time education course Yes 23 8.4
No 239 87.9
Refused to answer 10 3.7
Self reported chronic disease status as diagnosed by a western
allopathic doctor
Hypertension 45 16.5
Diabetes 19 7.0
Any heart diseases 16 5.9
Stroke 11 4.0
Asthma, emphysema, chronic bronchitis, or other chronic
respiratory diseases
31 11.4
Arthritis or any other chronic joint diseases 72 26.5
Depression, anxiety disorder or any other psychiatric diseases 41 15.1
Health services utilization in the past month Attended Chinese medicine consultation 222 81.6
Attended western medicine consultation 134 49.3
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(-0.724 vs. -0.750). Therefore, we were unable to esti-
mate MID for this item. For Symptom 1, Symptom 2,
Wellbeing and Profile, their MID were 0.894, 0.580,
0.263 and 0.516 respectively (all expressed in absolute
values). MDC from baseline to 2
nd week were 0.860
(Symptom 1), 0.894 (Symptom 2), 0.808 (Activity), 0.702
(Wellbeing) and 0.630 (Profile) respectively.
Result for 2
nd to 4
th week changes are presented in
table 5. Distribution of all mean change scores
demonstrated the expected increment down the
perceived global change gradient. For Symptom 1,
Symptom 2, Activity, Wellbeing and Profile scores, their
respective MID values were 0.187, 0.056, 0.286, 0.250
and 0.206 respectively (all expressed in absolute values).
MDC from 2
nd to 4
th week were 0.647 (Symptom 1),
0.700 (Symptom 2), 0.643 (Activity), 0.519 (Wellbeing)
and 0.478 (Profile). All MID and MDC values are
displayed graphically in Figure 1.
Discussion
In this study, we conducted a Chinese adaptation of the
English MYMOP questionnaire, and subsequently
assessed the Chinese version’s validity, responsiveness,
MID and MDC values in a sample of Chinese patients
using CM services.
Validity and Responsiveness of CMYMOP
The criterion validity of CMYMOP was demonstrated
by the negative correlation between CMYMOP Profile
scores and all SF-36 domain and summary scores at
baseline. Resembling validation result of the original
English version [8], strength of correlation between the
two scores was low to moderate. Only correlation coeffi-
cients between SF-36 General Health and Vitality
domain scores, and CMYMOP Profile scores reached
the conventional threshold of r ≥ 0.45 [25]. Such
Table 2 Criterion validity of CMYMOP: correlations
between CMYMOP profile scores and SF-36 scores when
questionnaires were first given
SF-36 Profile Score Pearson correlation coefficient *
1. Physical Functioning -0.345
2. Role, physical -0.359
3. Bodily pain -0.325
4. General Health -0.447
5. Vitality -0.454
6. Social functioning -0.391
7. Role, emotional -0.314
8. Mental health -0.378
9. Physical Composite Summary -0.368
10. Mental Composite Summary -0.374
*All p < 0.001
Table 3 Mean changes and effect sizes of CMYMOP and SF-36 scores and effect sizes at baseline, 2
nd and 4
th week
Scale Mean score at
baseline (SD)
Baseline vs. Follow up at 2
nd
week
2
nd week vs. 4
th week Baseline vs. Follow up at 4
th
week
CMYMOP Mean change in
score* (SD)
ES Mean change in
score* (SD)
ES Mean change in
score* (SD)
ES
Symptom 1 3.574 (1.523) -0.760 (1.719) 0.499 -0.193 (1.293) 0.126 -0.967 (1.859) 0.635
Symptom 2 3.597 (1.437) -0.623(1.788) 0.433 -0.075 (1.390) 0.052 -0.696 (1.819) 0.485
Activity 3.689 (1.551) -0.839 (1.615) 0.541 -0.118(1.286) 0.076 -0.972 (1.753) 0.627
Wellbeing 3.104 (1.439) -0.222 (1.403) 0.154 -0.188(1.037) 0.130 -0.424 (1.483) 0.295
Profile 3.376 (1.281) -0.488 (1.259) 0.381 -0.159(0.956) 0.124 -0.647 (1.401) 0.505
SF-36
Physical Functioning 47.50 (9.287) 1.711 (5.605) 0.184 0.698 (4.207) 0.075 2.419 (5.779) 0.261
Role, physical 42.29 (11.35) 1.570 (8.781) 0.138 0.802 (7.167) 0.071 2.372 (9.265) 0.209
Bodily pain 44.30 (11.03) 2.841(9.546) 0.258 0.895 (9.454) 0.081 3.735 (9.542) 0.339
General health 36.90 (9.285) 0.675(6.328) 0.073 1.047 (5.847) 0.113 1.722 (6.369) 0.185
Vitality 44.91 (10.21) 0.870(7.884) 0.085 1.060(7.356) 0.104 1.930 (9.047) 0.189
Social functioning 41.58 (11.54) 2.086(8.809) 0.181 0.478(8.413) 0.041 2.564 (9.259) 0.222
Role, emotional 39.83 (13.32) 2.087(10.571) 0.157 0.246(9.303) 0.018 2.338 (11.809) 0.176
Mental health 41.75 (10.63) 0.317(8.507) 0.030 1.189(7.796) 0.112 1.505 (9.336) 0.142
Physical Composite
Summary
44.85 (9.148) 1.876(5.707) 0.205 0.837(5.126) 0.092 2.743 (5.815) 0.300
Mental Composite
Summary
40.41 (11.78) 0.997(8.548) 0.085 0.683(7.903) 0.058 1.660 (9.510) 0.141
Key: SD: Standard Deviation, ES: Cohen’s Effect Size.
*Paired t test, all p ≤ 0.001
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difference between SF-36 and CMYMOP, in which the
former aims to measure generic health related quality of
life, and the later focuses on specific change of subjec-
tive symptoms. As an aspect of construct validity [26]
and longitudinal validity [27], the responsiveness of
CMYMOP and SF-36 also differed substantially in this
study. At all comparison timeframes (baseline vs. 2
nd
week, 2
nd vs. 4
th week, and baseline vs. 4
th week), ES of
all SF-36 domain and summary scores did not demon-
strate moderate change. On the contrary, ES of all
CMYMOP scorings achieved moderate or small changes
between baseline and 4
th week, implying a stronger
responsiveness compared to SF-36.
While it is generally expected that longer follow up
time is needed for capturing TCAM effect [28], our
results showed that CMYMOP ES values at baseline to
2
nd week interval were much higher than that of the 2
nd
to 4
th week interval. This suggests that most improve-
ment was detected at first two weeks of CM treatment.
Response shift at 4
th week follow up is a potential expla-
nation for observing less improvement, as previous
study has demonstrated that patients may raise their
improvement expectation at later follow up time [12].
An alternative explanation is the strength of MYMOP in
detecting improvement in acute conditions [8,29], in
which this property subsequently portrayed a clustering
of improvement at the first 2 weeks.
MID and MDC of CMYMOP
Concentration of improvement at the first two weeks is
also reflected in differences in MID values estimated from
early (baseline to 2
nd week) and late (2
nd to 4
th week)
anchors. Except for Wellbeing item in which MID from
two anchors were similar, MID values for Symptom 1,
Symptom 2 and Profile scores from early anchors were
substantially higher than that from the late anchors.
As mentioned in last paragraph, this may be a resultant
effect of response shift, or CMYMOP’s stronger ability in
detecting acute change. In this case, the later explanation
seems to be more plausible as our sample were attaching a
lower expectation on CM treatment effect at 4
th week —
even a very small change in CMYMOP score (e.g. 0.1) was
considered to be a slight improvement (table 5). From a
reliability perspective, the usefulness of late anchor MID
figures is doubtful as they are substantially lower than
their corresponding MDC values. At the 2
nd to 4
th week
timeframe, MDC figures ranged from 0.5 - 0.7, while MID
ranged from 0.06 - 0.29 (Figure 1). Hence the question of
whether a trivial mean change in CMYMOP score was
attributed to patient perceived improvement, or to mea-
surement errors, cannot be ascertained.
Table 4 Changes in mean CMYMOP scores from baseline to 2
nd week by categories of patient perceived change in
clinical condition
Mean (SD) change in score
Change rated by patients Much better n A little better n About the same n A little worse n Much worse n
Symptom 1 -1.833 (1.781) 36 -0.894
(1.672)
141 -0.300 (1.529) 80 0.833 (1.193) 12 N/A 0
Symptom 2 -1.296 (2.284) 27 -0.580
(1.596)
81 -0.381 (1.821) 42 -0.125 (1.356) 8 N/A 0
Activity -1.636 (1.590) 22 -0.724
(1.492)
87 -0.750 (1.832) 56 -0.571 (0.976) 7 N/A 0
Wellbeing -0.611 (1.609) 36 -0.263
(1.346)
137 -0.114 (1.377) 79 0.667 (1.303) 12 N/A 0
Profile -1.305 (1.541) 32 -0.516
(1.110)
136 -0.243 (1.280) 79 0.385 (0.832) 11 N/A 0
Key: SD: Standard Deviation, N/A: none of the patient reported “much worse”
Table 5 Change in mean CMYMOP scores from 2
nd week to 4
th week by categories of patient perceived change in
clinical condition
Mean (SD) change in score
Change rated by patients Much better n A little better n About the same n A little worse n Much worse n
Symptom 1 -0.892 (1.505) 37 -0.187 (1.250) 123 0.011(1.119) 88 0.333 (1.633) 15 N/A 0
Symptom 2 -0.696 (1.550) 23 -0.056 (1.241) 71 0.132 (1.359) 53 0.556 (1.944) 9 N/A 0
Activity -0.769 (1.177) 26 -0.286 (1.157) 84 0.314 (1.241) 51 0.571 (1.742) 14 N/A 0
Wellbeing -0.632 (1.364) 38 -0.250 (0.912) 116 0.047 (0.950) 85 0.267 (1.033) 15 N/A 0
Profile -0.719 (1.163) 35 -0.206 (0.859) 119 0.063 (0.841) 85 0.500 (1.157) 14 N/A 0
Key: SD: Standard Deviation, N/A: none of the patient reported “much worse”
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pared to MID also appeared in our early anchor results,
except for Symptom 1. Nevertheless, differences between
the two sets of values are of lesser magnitude (Figure 1).
These findings echo recent studies which showed how
variations in sample characteristics and analysis methods
contributed to large differences in minimally important
change values [30]. Given the current emphasis in using
anchor based method for establishing MID [22,23,30], a
tentative conclusion based on early anchor MID values is
preferred. However, as we were unable to estimate MID
for Activity domain scores, the corresponding MDC
value (0.702) may be used as a preliminary estimation.
Previous clinical studies using MYMOP as an outcome
measure [15,31] have made no explicit discussion on
MID, but gauged treatment effect size by referencing to
conventional standard of mean change size typical for a
seven points instrument (small change > 0.5; moderate
change > 1.0, large change > 1.5) [32]. It is obvious that
our tentative MID values are not compatible to this
convention uniformly. While the MID for Profile score
(0.516), Symptom 1 (0.894) and Symptom 2 (0.580) all
resembled to the conventional small change threshold,
MID for Wellbeing (0.263) was substantially lower. The
question of why patients were attaching a lower expec-
tation on Wellbeing as compared to Symptom 1 and 2
may partly be answered by our sample characteristics.
As we exclusively enrolled patients with reported symp-
toms in the past 14 days, all included patients had an
explicit intention in receiving treatments on specific
symptoms. Thus, the relative importance of enhancing
wellbeing could have been ranked lower when compared
to that of alleviating the main symptoms. In view of
such variations in patient expectations, further research
is needed to examine the legitimacy of calculating CMY-
MOP Profile score by averaging item scores with equal
weighting.
Limitations of this study
This study has several weaknesses. First, we did not per-
form a test-retest reliability assessment due to difficul-
ties in encouraging patients to repeat CMYMOP within
a short period of time. This inhibited us from estimating
MDC values using alternative methods like standard
error of measurement (SEM) calculation, which is less
dependent on data distribution[33,34]. Second, our
patient perceived change question (anchor question)
focused on global rating and thus ignored changes in
specific CMYMOP items. In other words, our anchor
question assumed all CMYMOP items to improve or
deteriorate in the same directions, and the validity of
this assumption requires further evaluation. Third, the
response rates at 4th week follow up were mediocre and
potential non-response bias cannot be ruled out. Forth,
we adopted a dual approach of data collection by using
both face to face and telephone interviews at follow ups.
The effect of such variation on data quality requires
further assessment, in which this would mandate an
independent study with sufficient sample size that allows
reliable comparison between the data collected by the
Figure 1 Summary of Minimally Important Difference and Minimally Detectable. Change Values of CMYMOP * MID of Activity item from 0-
2 week anchor question was not estimated.
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Page 7 of 9two approaches. Finally, in response to our pilot results,
we have changed the time frame of reference from the
original “past 7 days” to “past 2 weeks” at follow, so as
to facilitate our samples’ understanding on the items.
Similarly, a rigorous comparison is needed to assess the
effect of such changes on the results.
Conclusions
A Chinese version of MYMOP is developed using stan-
dard cultural adaptation methodology. In a CM clinical
setting, CMYMOP is a valid and responsive instrument
in capturing patient centred clinical changes within 2
weeks. Tentative MID values for Profile score ranged
from 0.52 to 0.56. Further researches are warranted (1) to
estimate Activity item MID, (2) to assess the test-retest
reliability of CMYMOP, and (3) to perform further MID
evaluation using multiple, item specific anchor questions.
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